Effect of amifostine on the acute toxicity reduction after megachemotherapy in children;Vliv amifostinu na redukci akutní toxicity při protinádorové megachemoterapii dětí

Casopis Lekaru Ceskych

Volumn 141, Issue 10, 2002, Pages 316-319

  Valkova J ^a   Stankova J ^a   Kavan, P ^a   Kabickova E ^a   Gajdos P ^a   Koutecky J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute toxicity reduction; Amifostine; Megachemotherapy

Indexed keywords

AMIFOSTINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; ETOPOSIDE; MELPHALAN; THIOTEPA;

ACUTE TOXICITY; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FEVER; HUMAN; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION;

ADOLESCENT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PROTECTIVE AGENTS; RETROSPECTIVE STUDIES;

EID: 0036272832     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children
2. A Phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer
3. Systemic inflammatory response syndrome associated with amifostine - Brief report
4. Fever and rash after amifostine therapy
5. Hypotensive mechanisms of amifostine
6. High dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study
7. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled Phase II trial
8. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation
9. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
10. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: Drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study
11. Amifostine can reduce mucosal damage after high dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study
12. Amifostine improves the antileukemic terapeutic index of mafosfamide: Implications for bone marrow purging
13. Amifostine protects primitive haematopoietic progenitors against chemotherapy cytotoxicity
14. Amifostine (Ethyol): Dosing, administration and patient management guidelines
15. Amifostine (WR-2721) selective protection against melphalan genotoxicity
16. Možnosti zlepšení výtěžku separací periferních progenitorových buněk - Zkušenosti kliniky dětské onkologie
17. Pharmacokinetics of amifostine and its metabolites in patients
18. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
19. Letter to the Editor: Lack of protection of proximal tubular cells by amifostine (ethyol) in ifosfamide-containing regimens
20. The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells
21. Determination of the cytoprotective agent WR-2721 (amifostine, ethyol) and its metabolites in human blood using monobromobimane fluorescent labelling and high-performance liquid chromatography
22. Randomized phase II study of weekly Cisplatin with or without ethyol in patients with advanced head and neck cancer